Literature DB >> 29492824

Inflammasome Activation by Methamphetamine Potentiates Lipopolysaccharide Stimulation of IL-1β Production in Microglia.

Enquan Xu1, Jianuo Liu1, Han Liu1, Xiaobei Wang2, Huangui Xiong3.   

Abstract

Methamphetamine (Meth) is an addictive psychostimulant abused worldwide. Ample evidence indicate that chronic abuse of Meth induces neurotoxicity via microglia-associated neuroinflammation and the activated microglia present in both Meth-administered animals and human abusers. The development of anti-neuroinflammation as a therapeutic strategy against Meth dependence promotes research to identify inflammatory pathways that are specifically tied to Meth-induced neurotoxicity. Currently, the exact mechanisms for Meth-induced microglia activation are largely unknown. NLRP3 is a well-studied cytosolic pattern recognition receptor (PRR), which promotes the assembly of the inflammasome in response to the danger-associated molecular patterns (DAMPs). It is our hypothesis that Meth activates NLRP3 inflammasome in microglia and promotes the processing and release of interleukin (IL)-1β, resulting in neurotoxic activity. To test this hypothesis, we studied the effects of Meth on IL-1β maturation and release from rat cortical microglial cultures. Incubation of microglia with physiologically relevant concentrations of Meth after lipopolysaccharide (LPS) priming produced an enhancement on IL-1β maturation and release. Meth treatment potentiated aggregation of inflammasome adaptor apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), induced activation of the IL-1β converting enzyme caspase-1 and produced lysosomal and mitochondrial impairment. Blockade of capase-1 activity, lysosomal cathepsin B activity or mitochondrial ROS production by their specific inhibitors reversed the effects of Meth, demonstrating an involvement of inflammasome in Meth-induced microglia activation. Taken together, our results suggest that Meth triggers microglial inflammasome activation in a manner dependent on both mitochondrial and lysosomal danger-signaling pathways.

Entities:  

Keywords:  Il-1β; Inflammasome; Methamphetamine; Microglia; NLRP3; Neuroinflammation

Mesh:

Substances:

Year:  2018        PMID: 29492824      PMCID: PMC6430126          DOI: 10.1007/s11481-018-9780-y

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  85 in total

Review 1.  Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy.

Authors:  Eeva-Liisa Eskelinen
Journal:  Mol Aspects Med       Date:  2006-09-14

2.  SN79, a sigma receptor antagonist, attenuates methamphetamine-induced astrogliosis through a blockade of OSMR/gp130 signaling and STAT3 phosphorylation.

Authors:  Matthew J Robson; Ryan C Turner; Zachary J Naser; Christopher R McCurdy; James P O'Callaghan; Jason D Huber; Rae R Matsumoto
Journal:  Exp Neurol       Date:  2014-02-06       Impact factor: 5.330

3.  A role for mitochondria in NLRP3 inflammasome activation.

Authors:  Rongbin Zhou; Amir S Yazdi; Philippe Menu; Jürg Tschopp
Journal:  Nature       Date:  2010-12-01       Impact factor: 49.962

4.  The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse.

Authors:  Patrick M Beardsley; Keith L Shelton; Elizabeth Hendrick; Kirk W Johnson
Journal:  Eur J Pharmacol       Date:  2010-04-23       Impact factor: 4.432

5.  Mitochondrial ROS govern the LPS-induced pro-inflammatory response in microglia cells by regulating MAPK and NF-κB pathways.

Authors:  Junghyung Park; Ju-Sik Min; Bokyung Kim; Un-Bin Chae; Jong Won Yun; Myung-Sook Choi; Il-Keun Kong; Kyu-Tae Chang; Dong-Seok Lee
Journal:  Neurosci Lett       Date:  2014-10-22       Impact factor: 3.046

6.  Microglial activation and chronic neurodegeneration.

Authors:  Melinda E Lull; Michelle L Block
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

7.  Methamphetamine causes microglial activation in the brains of human abusers.

Authors:  Yoshimoto Sekine; Yasuomi Ouchi; Genichi Sugihara; Nori Takei; Etsuji Yoshikawa; Kazuhiko Nakamura; Yasuhide Iwata; Kenji J Tsuchiya; Shiro Suda; Katsuaki Suzuki; Masayoshi Kawai; Kiyokazu Takebayashi; Shigeyuki Yamamoto; Hideo Matsuzaki; Takatoshi Ueki; Norio Mori; Mark S Gold; Jean L Cadet
Journal:  J Neurosci       Date:  2008-05-28       Impact factor: 6.167

8.  Partial attenuation of cytotoxicity and apoptosis by SOD1 in ischemic renal epithelial cells.

Authors:  Huan Ling Liang; Jody Arsenault; Jordan Mortensen; Frank Park; Christopher P Johnson; Vani Nilakantan
Journal:  Apoptosis       Date:  2009-10       Impact factor: 4.677

Review 9.  Understanding the mechanism of IL-1β secretion.

Authors:  Gloria Lopez-Castejon; David Brough
Journal:  Cytokine Growth Factor Rev       Date:  2011-10-22       Impact factor: 7.638

Review 10.  Interleukin-1 as a pharmacological target in acute brain injury.

Authors:  David Brough; Nancy J Rothwell; Stuart M Allan
Journal:  Exp Physiol       Date:  2015-07-14       Impact factor: 2.969

View more
  9 in total

Review 1.  The Crosstalk Between Neurons and Glia in Methamphetamine-Induced Neuroinflammation.

Authors:  Sai Shi; Tianzhen Chen; Min Zhao
Journal:  Neurochem Res       Date:  2022-01-04       Impact factor: 3.996

Review 2.  Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson's disease.

Authors:  Eun-Joo Shin; Ji Hoon Jeong; Yeonggwang Hwang; Naveen Sharma; Duy-Khanh Dang; Bao-Trong Nguyen; Seung-Yeol Nah; Choon-Gon Jang; Guoying Bing; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Arch Pharm Res       Date:  2021-07-20       Impact factor: 4.946

Review 3.  Lysosomal Stress Response (LSR): Physiological Importance and Pathological Relevance.

Authors:  Koffi L Lakpa; Nabab Khan; Zahra Afghah; Xuesong Chen; Jonathan D Geiger
Journal:  J Neuroimmune Pharmacol       Date:  2021-03-22       Impact factor: 4.147

4.  System xc- in microglia is a novel therapeutic target for post-septic neurological and psychiatric illness.

Authors:  Yoshinori Kitagawa; Kazuhiro Nakaso; Yosuke Horikoshi; Masaki Morimoto; Takuma Omotani; Akihiro Otsuki; Yoshimi Inagaki; Hideyo Sato; Tatsuya Matsura
Journal:  Sci Rep       Date:  2019-05-17       Impact factor: 4.379

5.  Methamphetamine-associated cognitive decline is attenuated by neutralizing IL-1 signaling.

Authors:  Arkadiusz Liśkiewicz; Marta Przybyła; Minseon Park; Daniela Liśkiewicz; Marta Nowacka-Chmielewska; Andrzej Małecki; Jarosław Barski; Joanna Lewin-Kowalik; Michal Toborek
Journal:  Brain Behav Immun       Date:  2019-03-15       Impact factor: 7.217

Review 6.  The Significance of NLRP Inflammasome in Neuropsychiatric Disorders.

Authors:  Yao Shen; Liyin Qian; Hu Luo; Xiaofang Li; Yuer Ruan; Runyue Fan; Zizhen Si; Yunpeng Chen; Longhui Li; Yu Liu
Journal:  Brain Sci       Date:  2022-08-10

7.  Role of C/EBP-β in Methamphetamine-Mediated Microglial Apoptosis.

Authors:  Xuebing Chen; Jiancong Lu; Xu Zhao; Chuanxiang Chen; Dongfang Qiao; Huijun Wang; Xia Yue
Journal:  Front Cell Neurosci       Date:  2019-08-21       Impact factor: 5.505

Review 8.  Interactions of neuroimmune signaling and glutamate plasticity in addiction.

Authors:  Cassandra D Gipson; Scott Rawls; Michael D Scofield; Benjamin M Siemsen; Emma O Bondy; Erin E Maher
Journal:  J Neuroinflammation       Date:  2021-02-21       Impact factor: 8.322

9.  Methamphetamine augments HIV-1 gp120 inhibition of synaptic transmission and plasticity in rat hippocampal slices: Implications for methamphetamine exacerbation of HIV-associated neurocognitive disorders.

Authors:  Ya Zheng; Benjamin Reiner; Jianuo Liu; Linda Xu; Huangui Xiong
Journal:  Neurobiol Dis       Date:  2022-03-22       Impact factor: 7.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.